Immunotherapy Side Effects May Be More Common Than Thought

Higher rates of adverse events observed for immune checkpoint inhibitors in real-world settings, compared to clinical trials.

Safe to Administer B12 Supplementation, Pemetrexed Infusions for Lung Cancers on Same Day

Mean changes in hematologic indices found similar regardless of same-day or prior administration of B12 supplementation in patients receiving pemetrexed for NSCLC or pleural mesothelioma.

Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials

Study suggests irAEs with PD-L1 therapy for NSCLC occur more frequently in real-world vs clinical trial populations.

Smoking, Lung Cancer Mortality Decline But Their Numbers Will Remain Significant

Trends are showing a decline in number of smokers and lung cancer mortality rate; however, simulation models show that the number of smokers and lung cancer-related deaths will still be high for 2015 to 2065.

E-cigarette Use Increasing Among Younger, Tobacco-Naïve Adults

A review of data from the Behavioral Risk Factor Surveillance System revealed that e-cigarette use among adult smokers has declined, but among nonsmokers 18 to 24 years old, use has increased in the same period.

Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC

A retrospective study of patients with NSCLC from 2 cancer centers demonstrates that concurrent use of corticosteroids with PD-1 or PD-L1 inhibitors at baseline decreases progression-free and overall survival for these patients.

Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC

In this randomized, double-blind, placebo-controlled study, researchers sought to determine the effect of including a checkpoint inhibitor in induction therapy for patients with extensive-stage small cell lung cancer.

Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer

Researchers determined that aggressive care at the end of life (EOL) leads to diminished quality of life, poor quality of care, and increased costs for patients with advanced lung cancer.

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)